The increased PSMB10 promotes the stemness maintenance of chemotherapeutic drug-resistant leukemia cells via the inhibition of SLC22A16-mediated drug endocytosis and RPL6/RPS6-MDM2-P21 pathway-initiated senescence, as well as the MHC-I protein degradation-induced escape of CTL killing. Here, MDM2 is linked to leukemia.